Shield Therapeutics (LON:STX) Stock Price Passes Below Fifty Day Moving Average – Here’s What Happened

Shares of Shield Therapeutics plc (LON:STX) passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of GBX 10.72 and traded as low as GBX 9.50. Shield Therapeutics shares last traded at GBX 9.96, with a volume of 2,648,759 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Peel Hunt reaffirmed a “buy” rating and set a GBX 15 target price on shares of Shield Therapeutics in a report on Friday, November 7th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, Shield Therapeutics currently has an average rating of “Buy” and an average price target of GBX 15.

Shield Therapeutics Stock Performance

The company has a debt-to-equity ratio of 3,691.50, a current ratio of 1.05 and a quick ratio of 2.16. The stock has a market cap of £106.36 million, a price-to-earnings ratio of -4.98 and a beta of 1.42. The firm has a fifty day moving average of GBX 10.72 and a 200 day moving average of GBX 8.20.

About Shield Therapeutics

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.